Stocks · News reference
Phibro Animal Health Corporation announced its financial results for the first quarter ended September 30, 2026, reporting net sales of $386.8 million and maintaining its financial guidance for the fiscal year ending June 30, 2027.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Phibro Animal Health (NASDAQ:PAHC) reported first-quarter financial results on Thursday. The transcript from the company’s first-quarter earnings call has been provided below.Benzinga APIs provide real-time access to
Filed: 2026-11-04 AccNo: 0001104659-26-122727 Size: 666 KB Item 2.02: Results of Operations and Financial Condition Item 5.07: Submission of Matters to a Vote of Security Holders Item 9.01: Financial Statements and Exhibits
The Board of Directors of Phibro Animal Health Corporation declared a quarterly cash dividend of $0.12 per share on its Class A and Class B common stock.
Becton Dickinson (BDX) is set to report Q4 fiscal 2026 results on Nov. 5, with EPS expected to grow 2.53% despite a 13% revenue decline. While Medical Essentials and Interventional segments show strength, China market challenges and a 200-basis-point Alaris revenue headwind are expected to weigh on quarterly performance. The company has a positive Earnings ESP of +0.21% and Zacks Rank #2, suggesting an earnings beat is unlikely despite historical performance.
Phibro Animal Health Corporation announced it will release its first quarter financial results on November 4, 2026, followed by a conference call and webcast on November 5, 2026.
Phibro Animal Health (PAHC) is gaining momentum from strong Animal Health segment growth, driven by the Zoetis MFA acquisition, vaccine expansion, and mineral nutrition demand recovery. However, the company faces headwinds from macroeconomic risks, trade policy uncertainties, and foreign exchange volatility that continue to pressure reported results.